[go: up one dir, main page]

ES2174027T3 - Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas. - Google Patents

Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.

Info

Publication number
ES2174027T3
ES2174027T3 ES96304702T ES96304702T ES2174027T3 ES 2174027 T3 ES2174027 T3 ES 2174027T3 ES 96304702 T ES96304702 T ES 96304702T ES 96304702 T ES96304702 T ES 96304702T ES 2174027 T3 ES2174027 T3 ES 2174027T3
Authority
ES
Spain
Prior art keywords
compound
macrolides
refers
compositions containing
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96304702T
Other languages
English (en)
Inventor
Ramune Marija Cobb
Christopher Leigh Schwartzkoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2174027(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2174027T3 publication Critical patent/ES2174027T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/843—Corynebacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A DETERMINADAS COMPOSICIONES ESTABLES DE VACUNAS QUE CONTIENEN UN COMPUESTO DE LACTONA MACROCICLICA, UN COMPUESTO DE MILBERNICINA Y UN COMPUESTO DE AVERMECTINA, O MEZCLAS DE LOS MISMOS; AL MENOS UN ANTIGENO; UN AGENTE DISPERSOR; UN ADYUVANTE; UN SOLVENTE ORGANICO SOLUBLE EN AGUA; Y SALINA O AGUA O MEZCLAS DE AMBAS. LA INVENCION TAMBIEN SE REFIERE A LAS COMPOSICIONES ESTABLES ANTES DESCRITAS DE UN COMPUESTO DE LACTONA MACROCICLICA, UN COMPUESTO DE MILBERNICINA Y UN COMPUESTO DE AVERMECTINA, O MEZCLAS DE LOS MISMOS, PERO SIN ANTIGENO. LA INVENCION TAMBIEN INCLUYE EL METODO PARA PREVENIR O CONTROLAR LA HELMINTIASIS, LAS INFECCIONES POR ACAROS Y ARTROPODOS ENDO Y ECTOPARASITOS Y ENFERMEDADES BACTERIANAS Y VIRALES EN ANIMALES DE SANGRE CALIENTE MEDIANTE LA ADMINISTRACION PARENTERAL DE LAS COMPOSICIONES DE LA INVENCION. LA INVENCION TAMBIEN SE REFIERE AL PROCESO DE PREPARACION DE LAS COMPOSICIONES DE LA INVENCION.
ES96304702T 1995-06-30 1996-06-26 Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas. Expired - Lifetime ES2174027T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60595P 1995-06-30 1995-06-30

Publications (1)

Publication Number Publication Date
ES2174027T3 true ES2174027T3 (es) 2002-11-01

Family

ID=21692234

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96304702T Expired - Lifetime ES2174027T3 (es) 1995-06-30 1996-06-26 Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.

Country Status (15)

Country Link
US (2) US5989566A (es)
EP (1) EP0750907B1 (es)
AR (1) AR003445A1 (es)
AT (1) ATE214603T1 (es)
AU (1) AU708464B2 (es)
BR (1) BR9602939A (es)
DE (1) DE69619894T2 (es)
DK (1) DK0750907T3 (es)
ES (1) ES2174027T3 (es)
NZ (1) NZ286896A (es)
PT (1) PT750907E (es)
RU (1) RU2213574C2 (es)
SI (1) SI0750907T1 (es)
UY (2) UY24268A1 (es)
ZA (1) ZA965539B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7349596A (en) * 1995-05-17 1996-12-11 International Centre of Insect Physiology and Ecology, The Novel method of enhancing efficiency of anti-arthropod agents against blood-feeding ectoparasites
CA2259469A1 (en) 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
US6790445B1 (en) 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
WO1999002182A2 (en) * 1997-07-10 1999-01-21 Biotech Australia Pty. Limited Non-aqueous vaccines
US6524592B2 (en) * 1997-10-17 2003-02-25 American Home Products Corporation Veterinary vaccines
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
GB9801109D0 (en) * 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1588167A4 (en) * 2003-01-16 2006-08-09 Univ Virginia SPERM-SPECIFIC LYSOCYLUM PROTEINS
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
NZ529177A (en) * 2003-10-24 2005-12-23 Agres Ltd Administration process for a delivery device that releases the active agent over several days
US20070141086A1 (en) * 2003-11-21 2007-06-21 Ohara Michael K Use of antibiotics as vaccine adjuvants
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
MX2008012651A (es) * 2006-03-30 2009-03-06 Embrex Inc Procedimientos y composiciones para vacunacion de aves de corral.
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090053335A1 (en) * 2007-04-13 2009-02-26 Chih-Hui Lin Herbal compositions for the inhibition of human immunodeficiency virus (hiv)
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5901115B2 (ja) * 2007-06-08 2016-04-06 オーストラリアン ポールトリー シーアールシー ピーティーワイ リミテッド クロストリジウム毒素ｎｅｔｂ
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
BR112012008185A2 (pt) * 2009-10-07 2016-08-16 Wyeth Llc composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
US10561720B2 (en) * 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3885011A (en) * 1971-12-29 1975-05-20 Janssen Pharmaceutica Nv Vaccine adjuvants
SU627610A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат землаково в.п. против клюстридиозов животных и птиц
NZ193807A (en) * 1979-05-31 1983-03-15 Ici Tasman Ltd Improving the response of ruminants to clostridial vaccine by administering tetramisole or levamisole
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS62294623A (ja) * 1986-02-26 1987-12-22 Nisshin Flour Milling Co Ltd サルモネラ感染症予防剤
ES2054664T3 (es) * 1986-03-12 1994-08-16 American Cyanamid Co Compuestos macrolidos.
DE3785936T2 (de) * 1986-03-25 1993-08-26 Sankyo Co Makrolid-derivate, ihre herstellung und ihre verwendung.
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
US4988824A (en) * 1989-09-11 1991-01-29 Maulding Donald R Process for the preparation of 23-(C1-C6 alkyloxime)-LL-F28249 compounds
FR2654339B1 (fr) * 1989-11-14 1994-10-28 Mayoly Spindler Laboratoires Nouveaux derives solubles et non toxiques des macrolides polyeniques basiques, leur preparation et leurs applications.
US5262400A (en) * 1991-06-20 1993-11-16 Merck & Co., Inc. 4α-substituted avermectin derivatives
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
NZ286896A (en) 1998-05-27
PT750907E (pt) 2002-08-30
EP0750907A2 (en) 1997-01-02
AU708464B2 (en) 1999-08-05
DE69619894D1 (de) 2002-04-25
RU2213574C2 (ru) 2003-10-10
EP0750907A3 (en) 1998-05-06
SI0750907T1 (en) 2002-08-31
ATE214603T1 (de) 2002-04-15
AR003445A1 (es) 1998-08-05
UY24281A1 (es) 1996-12-26
DK0750907T3 (da) 2002-07-08
AU5625696A (en) 1997-01-09
DE69619894T2 (de) 2002-11-14
EP0750907B1 (en) 2002-03-20
BR9602939A (pt) 1998-04-22
US5989566A (en) 1999-11-23
US20020102266A1 (en) 2002-08-01
UY24268A1 (es) 2001-10-25
US6746677B2 (en) 2004-06-08
ZA965539B (en) 1998-03-30

Similar Documents

Publication Publication Date Title
ES2174027T3 (es) Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.
AR003433A1 (es) Agente ectoparasiticida, procedimiento para la produccion de dicho agente uso de un compuesto contra insectos parasitos y garrapatas monofagas y para laproduccion de dicho agente.
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
SE8802985L (sv) Kemiska foereningar och foerfarande foer deras framstaellning
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
AR030947A1 (es) Guanidinas de acido cinamico substituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico asi como un medicamento que las contiene
GT199800207A (es) Nuevos derivados de la eritromicina.
ES2097297T3 (es) Isoquinolein-5-il-sulfonamidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
DK317382A (da) Fremgangsmaade til fremstilling af pyrrolidinderivater
LU88684I2 (fr) Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet )
NO20062779L (no) Vaksinesammensetning blandet med en alkylfosfatidylkolin
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
DK84181A (da) Derivater af 3,4,5-trihydroxypiperidin,fremgangsmaade til fremstilling deraf samt deres anvendelse som laegemidler samt til dyreernaering
ES2039267T3 (es) Dihidropiridinamidas, procedimiento para su preparacion y su empleo en medicamentos.
DE69331007D1 (de) Difluoroavermectin-derivate
DK429480A (da) Phosphonohydroxyeddikesyre fremgangsmaader til fremstilling deraf samt anvendelse deraf som laegemiddel
AR034557A1 (es) Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolina
ES2097127T3 (es) Formulaciones de administracion topica eficaces para el control de parasitos internos y externos de animales homotermos.
ES2056947T3 (es) Productos opticamente activos de derivados de 20,21-dinoreburnamenina, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
ES2104295T3 (es) Derivados ciclopeptidicos de la angiopeptina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2115625T3 (es) Sales por adicion de acidos cristalinas de esteres 1-(2,2-dimetil-propioniloxi)-etilicos de acido 3-cefemo-4-carboxilico puros en cuanto a los diastereoisomeros.
AR014320A1 (es) Compuestos de (2r,3s,4s,5r,6r,10r,11r)-2,4,6,8,10-pentametil-11-acetil-12, 13-dioxabiciclo[8.2.1]tridec-8-en-1-ona, medicamentos que contienen estoscompuestos y procedimiento para la preparacion de dichos compuestos
DK0408437T3 (da) 2-Alkyliminobenzothiazolinderivater, fremgangsmåder til deres fremstilling og lægemidler indeholdende disse forbindelser

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 750907

Country of ref document: ES